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Contribution of two independent MDM2-binding domains in
p14ARF to p53 stabilization
Marion A.E. Lohrum, Margaret Ashcroft, Michael H.G. Kubbutat* 
and Karen H. Vousden
The MDM2 protein targets the p53 tumor suppressor for
ubiquitin-dependent degradation [1], and can function
both as an E3 ubiquitin ligase [2] and as a regulator of
the subcellular localization of p53 [3]. Oncogene
activation stabilizes p53 through expression of the ARF
protein (p14ARF in humans, p19ARF in the mouse) [4],
and loss of ARF allows tumor development without loss
of wild-type p53 [5,6]. ARF binds directly to MDM2, and
prevents MDM2 from targeting p53 for degradation [6–9]
by inhibiting the E3 ligase activity of MDM2 [2] and
preventing nuclear export of MDM2 and p53 [10,11].
Interaction between ARF and MDM2 results in the
localization of both proteins to the nucleolus [12–14]
through nucleolar localization signals (NoLS) in ARF
and MDM2 [11–14]. Here, we report a new NoLS within
the highly conserved amino-terminal 22 amino acids of
p14ARF, a region that we found could interact with
MDM2, relocalize MDM2 to the nucleolus and inhibit
the ability of MDM2 to degrade p53. In contrast, the
carboxy-terminal fragment of p14ARF, which contains
the previously described NoLS [11], did not drive
nucleolar localization of MDM2, although this region
could bind MDM2 and weakly inhibit its ability to
degrade p53. Our results support the importance of
nucleolar sequestration for the efficient inactivation of
MDM2. The inhibition of MDM2 by a small peptide from
the amino terminus of p14ARF might be exploited to
restore p53 function in tumors. 
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Results and discussion
We learned from discussions with Weber et al. that mouse
p19ARF contains two independent MDM2-binding regions
within the exon-1b -encoded sequences [14]. To define the
MDM2-binding domains in human p14ARF, we expressed
fragments of p14ARF (Figure 1a) in the active site loop of
thioredoxin (Tx) [13,15]. Consistent with previous studies
of mouse and human ARF [9,12], we found that
Tx–ARF1–64, corresponding to the region of p14ARF
Figure 1
Domains of p14ARF necessary for binding MDM2 in vivo. (a) Structure
of p14ARF, showing the highly conserved amino-terminal 22 amino
acids (grey), and the p14ARF peptides that were cloned into the active
site loop of thioredoxin. (b) Western blot analysis of Tx–ARF proteins
coimmunoprecipitated with MDM2 protein. U2OS cells were
cotransfected with constructs encoding wild-type MDM2 and the
indicated Tx–ARF proteins. MDM2 was immunoprecipitated (IP) using
antibody SMP14, and Tx–ARF proteins were detected using an anti-
Myc antibody. IgG(L), position of the immunoglobulin light chain. The
loading controls show western blots of MDM2 and Tx–ARF proteins
contained in the lysates following incubation with antibody but before
immunoprecipitation; the IgG(L) band in the left panel became
apparent after a longer exposure.
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expressed from exon 1b , retained the ability to bind
cotransfected MDM2 (Figure 1b, left). This activity was
localized to the amino-terminal half of this region of
p14ARF; Tx–ARF1–34 retained the ability to bind MDM2
(Figure 1b, left), but this was lost in Tx–ARF35–64 (data
not shown). Comparison of human p14ARF with mouse
p19ARF revealed that the highest level of conservation
between the two proteins was within the first 22 amino
acids. Analysis of smaller p14ARF peptides showed that
residues 1–22 retained the ability to bind MDM2, whereas
Tx–ARF23–44 and Tx–ARF56–64 showed no evidence of
binding (Figure 1b, left). Analysis of the exon-2-encoded
sequences of p14ARF in Tx–ARF65–132 revealed a second
MDM2-binding site, although comparison of the coprecip-
itated Tx–ARF proteins with the total amount in the cell
showed that the Tx–ARF65–132 fragment bound MDM2
much less efficiently than Tx–ARF1–22 (Figure 1b, right).
Two MDM2-binding regions have also been described in
p19ARF but, in the mouse protein, both MDM2-interacting
domains are in the sequences encoded by exon 1b [14].
Interestingly, of the two MDM2-interacting domains in
the amino terminus of p19ARF, the higher affinity site is
located in the amino-terminal 1–14 amino acids [14].
Previous studies have shown that the NoLS in ARF is
important for its ability to inactivate MDM2 [11,12]. We
therefore examined the subcellular localization of the
p14ARF fragments in U2OS (Figure 2) and MCF-7 cells
(data not shown) by comparing the localization of the
Tx–ARF proteins with a nucleolar protein, B23. The
thioredoxin protein containing full-length p14ARF
(Tx–ARF1–132) was localized to the nucleolus like the
wild-type protein (Figure 2a–d). Analysis of proteins
containing amino-terminal p14ARF peptides showed that
each protein that contained the first 22 amino acids
localized to the nucleolus (Figure 2e–h,k,l). In contrast,
constructs expressing p14ARF peptides that failed to
interact with MDM2 (Tx–ARF35–64, Tx–ARF23–44
and Tx–ARF56–64) also failed to localize to the nucleo-
lus (Figure 2i,j,m–p). These proteins showed general
nucleoplasmic staining with some evidence of nucleolar
exclusion. Expression of the exon-2-encoded sequence
of p14ARF (Tx–ARF65–132), containing the previously
identified NoLS between amino acids 82–101 [11], also
showed some nucleolar localization, as expected,
although significant nucleoplasmic staining was seen for
this construct in all cells (Figure 2q,r). All of these pro-
teins showed the same patterns of subcellular localiza-
tion in MDM2/p53 null mouse embryo fibroblasts
(Supplementary material and data not shown), indicating
that their localization was not dependent on the NoLS
recently described in MDM2 [13,14]. The identification
of a previously undescribed NoLS in the amino terminus
of p14ARF is consistent with a recent study showing that
deletion of the amino-terminal 14 amino acids of p14ARF
severely compromises nucleolar localization [14]. 
The ability of ARF to inhibit MDM2 activity has been
associated with both binding of ARF to MDM2 and the
nucleolar localization of the ARF–MDM2 complex
[12,13]. We therefore examined the effect of the p14ARF
fragments on the subcellular localization of transfected
and endogenous human MDM2 (Figure 3 and data not
shown), and obtained identical results. Cotransfection of
full-length p14ARF in Tx–ARF1–132 resulted in a clear
relocalization of MDM2 from the nucleoplasm to the
nucleolus (Figure 3a–d), in agreement with the previ-
ously described function of the mouse and human pro-
teins [12,13]. Expression of each of the amino-terminal
Tx–ARF proteins that retained the ability to bind MDM2
and localize to the nucleolus also resulted in relocalization
of MDM2 to the nucleolus (Figure 3e–h,k,l). MDM2
expressed with non-binding thioredoxin-p14ARF proteins
(Tx–ARF35–64, Tx–ARF23–44 and Tx–ARF56–64)
remained in the nucleoplasm, with evidence of nucleolar
exclusion (Figure 3i,j,m–p). Interestingly, none of the
cells transfected with the exon-2-encoded region of
p14ARF in Tx–ARF65–132 showed nucleolar localization
of MDM2 (Figure 3q,r), despite the nucleolar/nucleoplas-
mic localization of Tx–ARF65–132 as seen in Figure 2q
(data not shown). These results therefore suggest that,
while binding of full-length p14ARF or the amino-terminal
region can reveal the NoLS in MDM2 [13,14], this is not
achieved through the weaker interaction of the carboxy-
terminal region of p14ARF with MDM2. Although we
could not detect nucleolar localization of MDM2 with the
exon-2-encoded fragment, Weber et al. showed that a
larger fragment of p14ARF, deleted of only the first 14
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Figure 2
Subnuclear distributions of p14ARF peptides in U2OS cells. The
indicated p14ARF constructs were transfected into U2OS cells, and
the cells stained with (a) anti-p14ARF rabbit serum IP1 and fluorescein
isothiocyanate (FITC)-conjugated anti-rabbit Ig antibody;
(c,e,g,i,k,m,o,q) anti-Myc antibody and FITC-conjugated anti-mouse Ig
antibody; or (b,d,f,h,j,l,n,p,r) anti-B23-antibody and Cy3-conjugated
anti-goat Ig antibody to visualize nucleoli.
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amino acids, retains some weak activity in relocalizing
MDM2 to the nucleolus[14], possibly reflecting a contri-
bution of other exon-1 b -encoded sequences. Defects in
nucleolar localization have also been reported in full-
length p14ARF proteins mutated in the carboxy-terminal
NoLS [11], and the nuclear localization signals in the
thioredoxin proteins may contribute to the efficiency of
nucleolar localization. Taken together, these studies
suggest that, although both amino- and carboxy-terminal
regions of 14ARF contribute to the binding and relocaliza-
tion of MDM2, the principal activity resides in the
amino-terminal domain encompassing residues 1–22,
which is also the region of ARF most highly conserved
between species. 
The localization of MDM2 to the nucleolus has been
shown to correlate with inhibition of the ability to target
p53 for degradation [12], although in vitro assays suggest
that the binding of ARF to MDM2 can directly inhibit the
E3 ubiquitin ligase activity of MDM2 [2]. We therefore
examined the ability of the p14ARF peptides to prevent
MDM2-mediated degradation of p53 by cotransfecting
them into cells with p53 and MDM2. MDM2-mediated
degradation of p53 was efficiently inhibited by coexpres-
sion of full-length p14ARF (Figure 4a). Analysis of smaller
regions of p14ARF showed that each amino-terminal
p14ARF peptide that retained the ability to bind and relo-
calize MDM2 to the nucleolus inhibited the degradation
of p53 (Figure 4a), although the smallest peptide (1–22)
was reproducibly slightly less efficient than the full-length
protein. In contrast, proteins containing p14ARF peptides
that failed to bind MDM2 (Tx–ARF35–64 and
Tx–ARF56–64) did not prevent MDM2-mediated degra-
dation of p53 (Figure 4a). The exon-2-encoded sequences
of p14ARF in Tx–ARF65–132 also showed some ability to
inhibit MDM2-mediated degradation of p53, although
this was considerably less efficient than exon-1b -encoded
sequences in Tx–ARF1–64 (Figure 4b) or the amino-ter-
minal peptide in Tx–ARF1–22 (Figure 4c). In addition to
targeting p53 for degradation, MDM2 also regulates its
own stability, and full-length ARF can stabilize MDM2 in
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Figure 3
The p14ARF-dependent nucleolar relocalization of MDM2. U2OS cells
were transfected with constructs encoding MDM2 and the indicated
p14ARF fragments. MDM2 localization was analyzed using
(a,c,e,g,i,k,m,o,q) antibody Ab-1 and FITC-conjugated anti-mouse Ig
antibody, and compared with (b,d,f,h,j,l,n,p,r) the nucleolar staining of the
anti-B23-antibody visualized with Cy3-conjugated anti-goat Ig antibody.
Figure 4
Tx–ARF proteins that relocalize and bind to MDM2 also inhibit MDM2-
mediated p53 degradation. (a) U2OS cells were transfected with
constructs expressing a FLAG epitope-tagged p53 fusion protein
(FLAG–p53), MDM2, the indicated Tx–ARF fusion proteins and the
green fluorescent protein (GFP). Protein expression was analyzed by
western blotting using an anti-FLAG antibody to detect FLAG–p53,
rabbit serum IP1 to detect p14ARF, and an anti-Myc antibody to detect
Tx–ARF proteins. Equal expression of GFP confirmed equal transfection
efficiencies. (b) U2OS cells were transfected with constructs
expressing FLAG–p53, MDM2, Tx–ARF1–64 and Tx–ARF65–132 as
indicated. Protein expression was analyzed by western blotting using an
anti-FLAG antibody to detect FLAG–p53, and an anti-Myc antibody to
detect the Tx–ARF proteins. (c) U2OS cells were transfected with
constructs expressing FLAG–p53, MDM2, full-length ARF,
Tx–ARF1–22 or Tx–ARF65–132 as indicated, and GFP. Protein
expression was analyzed by western blotting using antibody SMP14 to
detect MDM2, and an anti-FLAG antibody to detect FLAG–p53. Equal
expression of GFP confirmed equal transfection efficiencies.
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these experiments (Figure 4c) under conditions where
transfection of MDM2 alone barely increases the overall
protein levels. The amino-terminal 1–22 p14ARF peptide
that drove nucleolar localization of MDM2 also stabilized
MDM2, whereas Tx–ARF65–132, which was unable to
relocalize MDM2 from the nucleoplasm, only weakly
affected MDM2 stability. These results support the
importance of nucleolar localization for efficient inhibition
of MDM2-mediated degradation of p53. The degradation
activity of MDM2 could, however, be slightly inhibited by
Tx–ARF65–132 without efficient relocalization of MDM2
to the nucleolus.
We have shown that a peptide derived from the amino-
terminal 22 amino acids of p14ARF is sufficient to bind and
inhibit the degradation function of MDM2, drive relocal-
ization of MDM2 to the nucleolus and stabilize transcrip-
tionally active p53. The physiological role of the newly
identified amino-terminal NoLS in ARF is supported by a
naturally occurring germ-line mutation that results in the
expression of a fusion between amino acids 1–88 of
p14ARF and the carboxyl terminus of p16. This protein
inhibits MDM2 activity as efficiently as the wild-type
p14ARF protein and localizes to the nucleolus, despite the
loss of the previously described exon-2 encoded NoLS
(S. Brookes, S. Llanos and G. Peters, personal communica-
tion). It is becoming apparent that many human tumors
that retain wild-type p53 suffer loss of p14ARF, and are
therefore unable to activate p53 in response to abnormal
proliferative signals. Inhibition of MDM2-mediated
degradation of p53 in these cells may have therapeutic
benefit, and attempts have been made to directly inhibit
the interaction of MDM2 with p53. Our results present an
alternative possibility, where peptides like p14ARF 1–22 or
small molecules that interact with the p14ARF-binding
region of MDM2 could drive nucleolar localization of
MDM2 and provide an alternative mechanism through
which to activate p53 in some tumors.
Materials and methods
Plasmids
The backbone Tx vector has been described previously [13]. Construc-
tion of the Tx–ARF constructs is described in the Supplementary mate-
rial. Plasmids encoding human MDM2, human p53 and p14ARF have
been described previously [6,16]. Plasmid pEGFP N1 encoding GFP
was obtained from Clontech.
Protein analysis and immunofluorescence
The source of the antibodies used is described in the Supplementary
material. Coimmunoprecipitation to examine protein–protein associa-
tion, western blotting to determine total protein expression and
immunofluorescence to identify sub-cellular localization of the proteins
are described in the Supplementary material. 
Supplementary material
Supplementary material including additional methodological detail and
a figure showing subnuclear distributions of p14ARF peptides in mouse
embryo fibroblasts carrying null mutations in the p53 and MDM2 genes
is available at http://current-biology.com/supmat/supmatin.htm.
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